Patents by Inventor Erik J. SODERBLOM

Erik J. SODERBLOM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS
    Publication number: 20160331731
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle XIA, David Gooden, Erik J. Soderblom, Eric J. Toone, Neil L. Spector, Wayne F. Beyer, JR., Harold Walder
  • Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
    Patent number: 9439897
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 13, 2016
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle Xia, David Gooden, Erik J. Soderblom, Eric J. Toone, Neil L. Spector, Wayne F. Beyer, Jr., Harold Walder
  • USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS
    Publication number: 20150202294
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 23, 2015
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle XIA, David GOODEN, Erik J. SODERBLOM, Eric J. TOONE, Neil L. SPECTOR, Wayne F. BEYER, JR., Harold WALDER